Abemaciclib, a CDK4/6 inhibitor has demonstrated clinical activity in patients with HR+, HER2- advanced breast cancer both as monotherapy and in combination with endocrine therapy.1 In this exclusive video, Dr. Senthil Rajappa detects the results of MONARCH 3, a phase III placebo-controlled trial evaluating abemaciclib plus nonsteroidal aromatase inhibitor (NSAI) as the initial treatment in postmenopausal women with HR+/HER2- ABC. References 1. Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Trédan O, Chen SC, Manso L, Freedman OC.
MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. Journal of Clinical Oncology. 2017 Nov 10;35(32):3638-46. https://pubmed.ncbi.nlm.nih.gov/28968163/
